Epigenetics Market

The size of global epigenetics market in terms of revenue was estimated to be worth $1.8 billion in 2023 and is poised to reach $4.3 billion by 2028, growing at a CAGR of 18.3% from 2023 to 2028. The research study consists of an industry trend analysis, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

Growth in the market can be attributed to factors such as the favorable government initiatives and funding for epigenetics research and rising demand for epigenetic-based therapeutics.

Attractive Opportunities in the Epigenetics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Global Epigenetics Market Dynamics

Driver: Growing investment in research & development

Epigenetic research has the potential to advance the understanding of gene expression and its role in various diseases including cancer, neurological disorders, autoimmune diseases, and more. Pharmaceutical and biotechnology companies are allocating substantial resources to unravel the complexities of epigenetic mechanisms, aiming to harness their therapeutic potential. For instance In September 2023, Harbinger Health raised USD 140 million funding in Series B funding with founding investor Flagship Pioneering, alongside new global institutional investors including Pictet, Partners Investment, and Catalyst, among others. The company plans to use the new funds to support the completion of its Cancer ORigin Epigenetics-Harbinger Health (CORE-HH) clinical study. The firm's platform, HarbingerHx, uses machine learning to identify epigenetic patterns associated with tumor development. The company expects to launch its first product — a laboratory developed test for detection of early cancer — in 2025

Restraint: Limited Applications of epigenomic data in toxicology

The epigenetics data can provide valuable insights into the mechanisms of toxicity, but it may not always be useful in predicting the toxicity of a substance. Toxicoepigenetics is a relatively new field that investigates the epigenetic mechanisms of toxicity and is currently in its early stages, and more research is needed to fully understand the relationship between epigenetic modifications and toxicity. These profiling technologies are still relatively new and can be expensive and time-consuming. On the other side US Food and Drug Administration (FDA) have not yet established guidelines for the use of epigenetic data in toxicology testing which makes it difficult for companies to develop and commercialize epigenetic-based toxicology tests.

Opportunity: Integration of artificial intelligence and machine learning algorithm

Incorporating artificial intelligence (AI) and machine learning (ML) algorithms into the realm of epigenetics holds the promise of transforming comprehension of epigenetic mechanisms and their impact on a range of biological scenarios. Artificial intelligence (AI) is utilized to develop predictive models for diseases, including cancer. It analyses patient data, such as medical history and genetics, to assess disease risk and create customized treatment strategies. This enhances treatment effectiveness and minimizes potential complications. Several companies are offering innovative solutions including PacBio’s SMRT Analysis algorithms for epigenetics analysis and many are in race of developing for instance, In August 2023, FOXO (Australia) and Datarobot (US) entered a partnership for artificial intelligence (AI)-based epigenetic biomarker research in human longevity. Under this partnership both the companies will use epigenetics and AI to generate data-driven insights that help optimal health and longevity

Challenge: Concerns regarding quality of antibodies

Quality concerns surrounding antibodies have emerged as a significant impediment to the growth of the market. Quality concerns surrounding antibodies have emerged as a significant impediment to the growth of the market. The risk of antibodies exhibiting cross-reactivity with unintended targets can lead to inaccurate findings. Inconsistent sensitivity poses a potential obstacle to accurately detecting low-abundance molecules. Achieving reproducibility is essential for maintaining consistency across experiments, and the use of unreliable antibodies introduces unwarranted variability.  Furthermore, factors like batch-to-batch variations, improper storage conditions, and insufficient validation processes contribute to overall apprehensions about antibody quality, Additionally, the absence of standardized validation protocols and the limited availability of well-validated antibodies for emerging epigenetic markers compound these challenges.

Epigenetics Market Ecosystem

The kits & reagents segment is projected to hold the dominant position for epigenetics industry during the forecast period

On the basis of product & service, the epigenetics market is divided into various segments: kits & reagents, enzymes, instruments and accessories, software, and service. to the increasing development of easy-to-use, affordable, and advanced epigenetics kits & reagents are driving the growth of market.

North America was the largest regional market for epigenetics industry in 2022.

The epigenetics market is segmented into five major regions namely, North America, Europe, the Asia Pacific, Latin America, Middle East and Africa. In 2022, North America accounted for the largest share of the market, and this trend is expected to continue during the forecast period. Presence of epigenetic manufacturing companies and as favorable initiatives by government & private bodies for the development and adoption of NGS technologies are major factors contributing to the growth of market.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the epigenetics market include Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Merck KGaA (Germany), Active Motif, Inc. (US), Bio-Rad Laboratories Inc. (US), Promega Corporation (US), Revvity (US), Qiagen (Germany), New England Biolabs (US), Zymo Research Corporation (US), Diagenode SA (US), F. Hoffmann-La Roche Ltd (Switzerland), Epigentek Group Inc. (US), EpiCypher (US), Fios Genomics (UK), Genomescan (Netherlands), Creative Biogene (US), BPS Bioscience Inc. (US), Abnova Corporation (Taiwan), Creative Diagnostics (US), biomodal (UK), Integrated DNA Technologies Inc. (US) and Novogene Co Ltd. (China).

Scope of the Epigenetics Industry

This report categorizes the epigenetics market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

• Kits & Reagents
  • Antibodies
  • ChiP-seq Kits
  • Bisulfite Conversion Kits
  • Whole Genome Amplification Kits
  • 5-hmC and 5-mC Analysis Kits
  • Histones
  • Other Kits & Reagents
• Enzymes
  • DNA-modifying Enzymes
  • Protein-modifying Enzymes
  • Other Enzymes
• Instruments and Accessories
• Software
• Service

By Methods

• DNA Methylation
• Histone Modifications
• Other Methods (non-coding RNA and chromatin remodeling)

By Technique

• NGS
• PCR & qPCR
• Mass Spectrometry
• Sonication
• Other Techniques (magnetic separators and microarrays)

By Application

• Oncology
• Metabolic Diseases
• Immunology
• Developmental Biology
• Cardiovascular Diseases
• Other Applications (neurology, infectious diseases, and gynecology)

By End User

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Hospitals & Clinics

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (ROE)
• Asia Pacific
  • Japan
  • South Korea
  • China
  • India
  • Rest of Asia Pacific
•  Latin America
  • Brazil
  • Mexico
  • RoLATAM
• Middle East
• Africa

Recent Developments of Epigenetics Industry

• In August 2023, PacBio (US) acquired Apton Biosystems (US)  to accelerate the development of a next-generation, high-throughput, short-read sequencer.
• In March 2022, Thermofisher Scientific Inc (US) launched the CE IVD Marked Next Generation Sequencing Instrument designed to be used in in clinical laboratories to perform both diagnostic testing and clinical research on a single instrument
• In January 2022, Illumina, Inc. (US) entered into an agreement with SomaLogic (US) to introduce SomaScan Proteomics Assay in high throughput next-generation sequencing (NGS) platforms manufactured by Illumina

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst